Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768079 | 0.87 | HRH3 (0.84) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL14488615 | 0.85 | TSHR (0.48) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL1204908 | 0.82 | HRH3 (0.69) | HRH3 | |
| SCHEMBL20470512 | 0.82 | HRH3 (0.61) | HRH3HDAC8HDAC6 | |
| SCHEMBL2876380 | 0.82 | HRH3 (0.61) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL7315600 | 0.81 | HRH3 (0.50) | HRH3HDAC8HDAC6 | |
| SCHEMBL1822450 | 0.81 | HRH3 (0.67) | HRH3HDAC8HDAC6PYCR1ACHE | |
| SCHEMBL12680476 | 0.80 | HRH3 (1.00) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL5926009 | 0.80 | HRH3 (0.73) | HRH3HDAC8HDAC6PYCR1CNR2 | |
| SCHEMBL28510659 | 0.79 | HRH3 (0.41) | HRH3HDAC8HDAC6PYCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110938076-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-112898308-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-110759916-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-110938076-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110759916-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| CN-106661034-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2017-05-10 | — | — | CN | disclosed |
| CN-105367576-A | Pyrrolopyrimidine compounds as TLR7 agonists | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2016-03-02 | — | — | CN | disclosed |
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120029191-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2007104695-A1 | QUINOLIN-4-YLHYDRAZINE DERIVATIVES AS ANTIMALARIAL AGENT | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | HRH3 4/4885HDAC8 1185/4885HDAC6 932/4885 |
| US-20120029191-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | HRH3 4/4885HDAC8 1185/4885HDAC6 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.